COPD: LPS neutrophil chemotaxis model (inhaled)

Discovery

A key hallmark of COPD is airway neutrophilia – administration of LPS induces neutrophil chemotaxis to the lungs.

In the short (1 day) acute model of inflammation, LPS can be administered as either a nebulized aerosol or via the intratracheal route.

Validated positive controls – budesonide, dexamethasone, roflumilast and fluticasone propionate.

COPD: LPS neutrophil chemotaxis model (inhaled)

Study Design
Species/Strain	SD rat, Balb/c mouse, C57BL/6J mouse, guinea pig
Model	LPS induced Neutrophil Chemotaxis
Relevant Use	Assessing novel anti-inflammatories
Readouts Available	BAL differential cell counts and BAL cytokines

Study data generated by Labcorp Huntingdon Pharmacology.

Molecule or Product Type

Biologics, Small Molecule

Models

Guinea Pig, Mouse, Rat

Administration Routes

Dermal, Dietary, Gavage, Implant, Infusion, Inhalation, Intracranial, Intracutaneous, Intramuscular, Intranasal, Intraperitoneal, Intrathecal, Intratracheal, Intravenous, Ocular, Rectal, Subcutaneous, Vaginal

Regulatory

IND & CTA, NDA & BLA, Post-Market

Industry Market

Pharma

Phase

Discovery, Nonclinical

Related Models

Request a Quote

About our nonclinical animal research models: We provide the utmost care for our research animals and actively pursue advances in animal welfare. As well as ensuring the highest scientific, ethical and regulatory standards, selection of appropriate animal research models for development research is critical to developing safe and effective treatments, devices and products that protect and save lives. Just as we have ethical committee oversight for human trials, we have ethical committees overseeing all aspects of our global animal care and use programs. All of our core, nonclinical facilities are accredited by AAALAC. Learn more about our commitment to replacing, reusing and refining nonclinical research models.